Reduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: phase 2 randomized trial results1

Reduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: phase 2 randomized trial results1

Elevated apoC-III levels predict increased cardiovascular risk when present on LDL and HDL particles. We developed novel high-throughput chemiluminescent ELISAs that capture apoB, lipoprotein (a) [Lp(a)], and apoA-I in plasma and then detect apoC-III on these individual lipoproteins as apoCIII-apoB,...

Full description

Bibliographic Details
Main Authors: Xiaohong Yang, Sang-Rok Lee, Yun-Seok Choi, Veronica J. Alexander, Andres Digenio, Qingqing Yang, Yury I. Miller, Joseph L. Witztum, Sotirios Tsimikas
Format: Article
Language:English
Published: Elsevier 2016-04-01
Series:Journal of Lipid Research
Subjects:
hypertriglyceridemia
triglycerides
remnant lipoproteins
antisense oligonucleotides
cardiovascular disease
familial chylomicronemia syndrome
Online Access:http://www.sciencedirect.com/science/article/pii/S0022227520354250

Internet

http://www.sciencedirect.com/science/article/pii/S0022227520354250

Similar Items